Aptahem starts close collaboration with leading research groups at the Nencki Institute in Warsaw

Aptahem today announced that an extensive collaboration has begun with the Nencki Institute of Experimental Biology. Aptahem and various expert groups within the Institute will jointly examine the effects of the company’s developmental drug candidate, APTA-1. The Nencki Institute has the highest rankings for European research institutes, A +, and is among the leaders in molecular neurobiology, having two “European Centres of Excellence”.

This collaboration gives Aptahem access to leading international expertise, enabling the implementation of a thorough evaluation of APTA-1’s biological effects, both in cells and in animal models. Designs for a joint study have been submitted and the studies will begin after the authority’s ethical approval.

Michael Lindstam, CEO of Aptahem explains that this very valuable cooperation gives the company an opportunity to, among other things, clarify the anti-inflammatory properties of APTA-1. It is these anti-inflammatory properties that are central to the successful treatment of diseases like stroke.

For further information:
Michael Lindstam, CEO Aptahem AB
Tel: + 46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem is developing drug candidates for the treatment and prevention of diseases caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke, and heart failure. Thrombosis, also called clot, is the medical term for an increased and unhealthy coagulation of blood cells that cause more than 30 percent of all deaths worldwide. Thrombosis occurs either through genetic inheritance or by thrombosis occurs in conjunction with surgery, trauma, due to medication or by the victim suffering from a disease such as cancer. The company holds patents for Europe, China, the United States and Canada and the patent application in India.

Forward-looking statements
This communication contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as well as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.